Patent medicine the patent medicines, some of their makers began replacing the opium tincture laudanum with acetanilide, a particularly toxic non-steroidal anti-inflammatory drug with analgesic as well as antipyretic properties that had been introduced into medical practice under the name "Antifebrin" by A. Cahn and P. Hepp in 1886. But this ingredient change probably killed more of the nostrum's users than the original narcotics did, since acetanilide not only caused an alarming cyanosis due to methemoglobinemia but was later discovered to cause liver and kidney damage. The occasional reports of acetanilide-induced cyanosis prompted the search for supposedly less toxic aniline derivatives, such
Personalized medicine of personalised medicine to further fields of medicine, which requires the interdisciplinary cooperation of experts from specific fields of research, such as medicine, clinical oncology, biology, and artificial intelligence. The FDA has already started to take initiatives to integrate personalised medicine into their regulatory policies. An FDA report in October 2013 entitled, “"Paving the Way for Personalized Medicine: FDA’s role in a New Era of Medical Product Development",” in which they outlined steps they would have to take to integrate genetic and biomarker information for clinical use and drug development. They determined that they would have to develop specific regulatory